A real-world snapshot of where your biomarker stands today
NeoGenomics Biomarker Briefs deliver concise, publication-ready prevalence and testing trend analyses, scoped to a single biomarker and tumor type, drawn directly from our clinicogenomic database. The fastest way to get defensible, lab-confirmed biomarker intelligence without commissioning a full data study.
Understand the current testing landscape before your therapy reaches the market. Know where testing volume is highest, where concordance gaps exist, and what the eligible population actually looks like in practice.
A structured, citable biomarker prevalence analysis ready for internal scientific briefings, advisory boards, or as a data exhibit in a manuscript or abstract.
Fast, defensible prevalence data for payer dossier sections, budget impact models, and burden-of-disease frameworks, without commissioning a full RWE study.
Validate biomarker prevalence assumptions before I/E criteria are locked. So you can understand whether the eligible population in the community setting matches what was assumed at protocol design.
